New Recombinant XYNTHA Now Available for Patients with Hemophilia A
...advised to consult with their health care professional and to bring an adequate supply of XYNTHA for anticipated treatment. Indication for ReFacto refacto is indicated for the control and prevention of hemorrhagic episodes and for surgical prophylaxis and for short-term routine prophylaxis to reduce the ...ReFacto® Antihemophilic Factor (recombinant)
Learn about the prescription medication Refacto (Antihemophilic Factor), drug uses, dosage, side effects, drug interactions, warnings, and patient labeling.Refacto (Antihemophilic Factor) - Drug Info, Side Effects, Research ...
Refacto (Antihemophilic Factor) - Drug Info, Side Effects, Research, Clinical Trials ... ReFacto has in vitro functional characteristics comparable to those of ...ReFacto - definition of ReFacto by the Free Online Dictionary ...
Information about ReFacto in the free online English dictionary and encyclopedia. ... ReFacto. Refactor. Refactor. Refactorable number. Refactored. Refactoring ...WYE Biovitrum AB announces extension of ReFacto supply agreement with Wyeth
TradingMarkets News for WYE - Biovitrum AB announces extension of ReFacto supply agreement with Wyeth ... ReFacto, the agreement also includes Xyntha/ReFacto ...